

Poster presentation

Open Access

Differences in therapeutic approach to juvenile dermatomyositis between Europe and Latin America

L Trail^{*1}, C Ferrari¹, R Cuttica², MM Katsicas³, R Russo³, M Bandeira⁴, V Ferriani⁵, S Oliveira⁶, C Saad-Magalhaes⁷, CA Silva⁸, V Baca⁹, R Burgos-Vargas¹⁰, E Solis-Vallejo¹¹, S Maillard¹², C Pilkington¹², R Barcellona¹, M Beltramelli¹, L Breda¹, C Bruno¹, R Cimaz¹, E Cortis¹, R Gallizzi¹, F Garofalo¹, A Meini¹, R Podda¹, A Stabile¹, A Martini¹ and A Ravelli¹

Address: ¹Italian Pediatric Rheumatology Study Group, Italy, Italy, ²Hospital General de Ninos Pedro de Elizalde, Buenos Aires, Argentina, ³Hospital Garrahan, Buenos Aires, Argentina, ⁴Hospital Pequeno Principe, Curitiba, Brazil, ⁵Hospital da Universidade, Ribeirao Preto, Brazil, ⁶Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ⁷Hospital das Clínicas UNESP, Botucatu, Brazil, ⁸Hospital Das Clinicas, Sao Paulo, Brazil, ⁹CMN Siglo XXI, Mexico City, Mexico, ¹⁰Hospital General de México, Mexico City, Mexico, ¹¹CMN La Raza, Mexico City, Mexico and ¹²Great Ormond Street Hospital, London, UK

* Corresponding author

from 15th Paediatric Rheumatology European Society (PreS) Congress
London, UK. 14–17 September 2008

Published: 15 September 2008

Pediatric Rheumatology 2008, **6**(Suppl 1):P214 doi:10.1186/1546-0096-6-S1-P214

This abstract is available from: <http://www.ped-rheum.com/content/6/S1/P214>

© 2008 Trail et al; licensee BioMed Central Ltd.

Objective

To investigate the differences in the therapeutic approach to juvenile dermatomyositis (JDM) between pediatric rheumatology centers in Europe (EU) and Latin America (LA).

Methods

490 patients with JDM and disease duration > 2 years seen in 27 centers in EU (Italy, UK) and LA (Argentina, Brazil, Mexico) after 1980 were enrolled in a multinational, multicenter study aimed to investigate the long-term disease outcome. Median follow-up duration was 7.7 years (range 2–25.2 years). Gender ratio, onset age, and follow-up duration were comparable between EU and LA patients. At study visit, EU patients had a greater frequency of active disease, as measured with MDAA (51.1% vs. 35.2%) and DAS (64.8% vs. 54%), whereas LA patients had a greater frequency of muscle weakness, as measured with the CMAS (62.9% vs. 44.3%), and muscle damage, as measured with the MDI (41% vs. 30.1%).

Results

Table 1 shows the frequency of drugs administered to JDM patients in EU and LA centers.

Conclusion

Use of pulse iv steroids, CyA, AZA and CPM was more common in EU centers, whereas LA centers used more frequently MTX and AM. EU and LA centers administered iv Ig with equal frequency.

Table 1: Frequency of drugs administered to JDM patients in EU and LA centers

	Oral/iv steroids	Pulse iv steroids	MTX	CyA	Iv Ig	AM	AZA	Oral CPM	Pulse iv CPM
EU (N = 246)	97.6	50	50.8	35	17.1	26	13.4	5.3	8.5
LA (N = 236)	99.6	33.2	61.4	15.7	17.4	39	5.9	2.1	4.2

MTX: methotrexate; CyA: cyclosporine A; AM: antimalarials; AZA: azathioprine; CPM: cyclophosphamide

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

